Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of MOXR0916 plus atezolizumab vs placebo plus atezolizumab in urothelial carcinoma
2016-004165-58Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing MOXR0916 plus atezolizumab with Placebo plus atezolizumab (2 arms). Primary endpoints: Progression-free survival (all PD-L1) and Overall survival (all PD-L1). Started Jan 2017; status: completed.
02
Drugs
Vonlerolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2016-004165-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004165-58.